The peptides according to the invention are of the X- (Xaa1) n-Pro * -Xaa2-Y type, with: • n = 0, 1 or 2； Xaa1 is: a hydrophobic amino acid chosen from Alanine (Ala, A), Valine (Val, V), Methionine (Met, M), Leucine (Leu, L), Isoleucine (Iso, I ), Phenylalanine (Phe, F), Proline (Pro, P) and analogs or derivatives thereof； or - a polar amino acid selected from Serine (Ser, S), Threonine (Thr, T), Tyrosine (Tyr, Y), Asparagine (Asp, N), Glutamine (Glu, Q) and derivatives thereof and the like thereof； when n = 2 the two amino acids Xaa1 may be identical or different； Xaa2 is: a hydrophobic amino acid chosen from Alanine (Ala, A), Valine (Val, V), Methionine (Met, M), Leucine (Leu, L), Isoleucine (Iso, I ), phenylalanine (Phe, F), and analogs or derivatives thereof； a basic amino acid chosen from Arginine (Arg, R), Lysine (Lys, K) and Histidine (His, H) and the derivatives and analogs thereof； At the N-terminal end of the peptide, X is chosen from H, -CO-R 1 and -SO 2 -R 1； At the C-terminal end of the peptide, Y is chosen from OH, OR 1, NH 2, NHR 1 or NR 1 R 2, R 1 and R 2 being, independently of one another, chosen from an alkyl, aryl, aralkyl, alkylaryl and alkoxy group； and aryloxy, which may be linear, branched, cyclic, polycyclic, unsaturated, hydroxylated, carbonylated, phosphorylated and / or sulfurized, said group possibly having in its backbone a heteroatom, in particular O, S and / or N； • Pro * corresponding to Proline, an analogue or derivative thereof； excluding peptides in which X = H and Y = OH and excluding Pal-PR-OH.Les peptides selon l'invention sont du type X-(Xaa1)n-Pro*-Xaa2-Y, avec : • n = 0, 1 ou 2 ； • Xaa1 est : - un aminoacide hydrophobe choisi parmi l'Alanine (Ala, A), la Valine (Val, V), la Méthionine (Met, M), la Leucine (Leu, L), l'Isoleucine (Iso, I), la Phénylalanine (Phe, F), la Proline (Pro, P) et les analogues ou dérivés de ceux-ci ； ou - un aminoacide polaire choisi parmi la Sérine (Ser, S), la Thréonine (Thr, T), la Tyrosine (Tyr, Y
